To the Editor BTK inhibition and CD19-directed chimeric antigen receptor (CAR) T-cell therapy represent essential treatments for relapsed/refractory (R/R) mantle cell lymphoma (MCL) and have achieved impressive response rates [1]. Unfortunately, most patients eventually relapse due to therapy resistance, immune evasion, or waning efficacy [2]. Bispecific antibodies are being developed for relapsed disease, with multiple approved or clinically advanced candidates [3, 4].
Yue Fei
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Yue
Contact Yue, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack